Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyridostigmine Exercise Response in ME/CFS
NCT03674541Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Jan 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) comparing Pyridostigmine with Placebo (2 arms). Primary endpoint: Change in Peak Oxygen Uptake. Started Jan 2020; status: completed.
02
Drugs
pyridostigmine
03
Conditions
myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Beyond the preview
Go deeper on NCT03674541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674541.